Boston Scientific Corp. (BSX) Financials
Key financial figures for Boston Scientific Corp. (Q3 2026).
Boston Scientific Q3 2026 net sales rose 1.5% to $5.138B on a reported, operational and organic basis, and full-year 2026 guidance was cut to about 3.75% organic growth and adjusted EPS of $3.16 to $3.18 after an August cybersecurity incident. Net sales were $5.138B, up 1.5% on a reported, operational and organic basis versus $5.065B a year ago; the company's prior Q3 guide (per the Q2 release) was 3% to 5% growth, so growth came in below it. Adjusted EPS was $0.73 versus $0.75 a year ago, and below the company's prior Q3 guide of $0.80 to $0.82; GAAP diluted EPS was $0.40 versus $0.51, with $81M of litigation-related net charges, $63M of restructuring net charges and $39M of intangible asset impairment charges in operating expenses. On the outlook: Full year 2026: net sales growth of approximately 4.25% reported and approximately 3.75% organic; adjusted EPS of $3.16 to $3.18. Fourth quarter 2026: net sales change of approximately (3.0) to (1.0) percent on a reported and organic basis; adjusted EPS of $0.77 to $0.79. Figures are for Q3 2026, as Boston Scientific Corporation reported them.
- Revenue
- $5.1B
- Net Income
- $578M
- EPS
- $0.40
- Total Assets
- $45.5B
- Operating Cash Flow
- $1.0B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $5.1B | $578M | $0.40 | 16.12% | $868M |
| Q2 FY2026 | $5.4B | $907M | $0.61 | 21.65% | $1.3B |
| Q1 FY2026 | $5.2B | $1.3B | $0.90 | 20.6% | $171M |
| Q4 FY2025 | $5.3B | $668M | $0.45 | 22.81% | $1.0B |
| Q3 FY2025 | $5.1B | $755M | $0.51 | 20.73% | $1.2B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $20.1B | $2.9B | $1.94 | 18% | $3.7B |
| FY2024 | $16.7B | $1.9B | $1.25 | 15.73% | $2.6B |
| FY2023 | $14.2B | $1.6B | $1.07 | 16.45% | $1.7B |
Frequently asked questions
What was Boston Scientific Corporation's revenue last quarter?
Boston Scientific Corporation reported revenue of $5.14 billion for Q3 FY2026, up 1.4% from the same period a year earlier.
Is Boston Scientific Corporation profitable?
Yes. Boston Scientific Corporation reported net income of $578.0 million for Q3 FY2026, a net margin of 11.25% on revenue.
How has Boston Scientific Corporation's margin trended?
Operating margin was 16.12% in Q3 FY2026, compared with 20.73% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Boston Scientific Corporation generate?
Boston Scientific Corporation generated free cash flow of $868.0 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Boston Scientific Corp. on SentiSense, with up to forty quarters and twenty fiscal years of history.